Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC (LSE: HIKM) is a pharmaceutical company headquartered in Amman, Jordan. The company develops, manufactures, and markets both branded and generic pharmaceutical products worldwide. Its shares are listed on the London Stock Exchange and trade in GBP (GBX).

Recent Market Performance

On 26 November 2025, the price of Hikma’s shares was 1,600 GBX. The 52‑week high reached 2,360 GBX on 12 February 2025, while the 52‑week low fell to 1,522 GBX on 5 November 2025. The price‑earnings ratio stood at 12.59. The market capitalisation of the company was reported as 3.54 billion GBP.

Investor Returns over the Past Decade

A recent analysis from Finanzen.net examined the performance of an investment made ten years prior to 26 November 2025. On 26 November 2015 the closing price of Hikma was 21.51 GBP. An investment of 10,000 GBP at that time would have purchased 464.9 shares (rounded). Using the closing price of 16.00 GBP on 25 November 2025, the value of that position would be 7,438.40 GBP. This represents a decline of 25.62 percent over the decade, reflecting a significant loss for long‑term holders.

Market Context

The broader FTSE 100 index recorded a modest rise of 0.18 percent at 9,626.46 points on 26 November 2025, with an overall market capitalisation of 2.732 trillion Euro. The index’s performance for the year to date was 0.909 percent, indicating a relatively stable but slowly growing market environment.

Industry Outlook

While Hikma’s specific product pipeline is not detailed in the available news, several industry reports highlight growth areas in pharmaceuticals:

  • mTOR inhibitors are projected to reach a market value of US $9.71 billion by 2029, suggesting opportunities in oncology and immunology sectors.
  • Glycopeptide antibiotics are expected to grow at a CAGR of 9.2 % from 2025 to 2029, with a projected revenue of US $5.38 billion by 2029.
  • Quinolone antibiotics also show growth prospects, as indicated by recent market forecasts.

These developments provide a backdrop for Hikma’s potential expansion in both branded and generic drug markets.

Summary

Hikma Pharmaceuticals PLC continues to trade on the London Stock Exchange with a market capitalisation of approximately 3.54 billion GBP. Despite a 25.62 percent decline for long‑term investors over the past decade, the company operates within a pharmaceutical sector that is experiencing growth in key therapeutic areas such as mTOR inhibitors, glycopeptide antibiotics, and quinolones. The company’s performance will likely remain influenced by broader market movements in the FTSE 100 and the evolving dynamics of the global pharmaceutical industry.